Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre, Maastricht, the Netherlands.
BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD.
Diabetes Care. 2021 Jun;44(6):1334-1343. doi: 10.2337/dc20-2887. Epub 2021 Apr 15.
SGTL2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes. The underlying mechanism may involve caloric restriction-like metabolic effects due to urinary glucose loss. We investigated the effects of dapagliflozin on 24-h energy metabolism and insulin sensitivity in patients with type 2 diabetes.
There were 26 patients with type 2 diabetes randomized to a 5-week double-blind, crossover study with a 6- to 8-week washout. Indirect calorimetry was used to measure 24-h energy metabolism and the respiratory exchange ratio (RER), both by whole-room calorimetry and by ventilated hood during a two-step euglycemic-hyperinsulinemic clamp. Results are presented as the differences in least squares mean (95% CI) between treatments.
Evaluable patients ( = 24) had a mean (SD) age of 64.2 (4.6) years, BMI of 28.1 (2.4) kg/m, and HbA of 6.9% (0.7) (51.7 [6.8] mmol/mol). Rate of glucose disappearance was unaffected by dapagliflozin, whereas fasting endogenous glucose production (EGP) increased by dapagliflozin (+2.27 [1.39, 3.14] μmol/kg/min, < 0.0001). Insulin-induced suppression of EGP (-1.71 [-2.75, -0.63] μmol/kg/min, = 0.0036) and plasma free fatty acids (-21.93% [-39.31, -4.54], = 0.016) was greater with dapagliflozin. Twenty-four-hour energy expenditure (-0.11 [-0.24, 0.03] MJ/day) remained unaffected by dapagliflozin, but dapagliflozin reduced the RER during daytime and nighttime, resulting in an increased day-to-nighttime difference in the RER (-0.010 [-0.017, -0.002], = 0.016). Dapagliflozin treatment resulted in a negative 24-h energy and fat balance (-20.51 [-27.90, -13.12] g/day).
Dapagliflozin treatment for 5 weeks resulted in major adjustments of metabolism mimicking caloric restriction, increased fat oxidation, improved hepatic and adipose insulin sensitivity, and improved 24-h energy metabolism.
SGTL2 抑制剂可增加尿糖排泄,并对心血管和肾脏结局有有益影响。其潜在机制可能涉及由于尿糖丢失而产生的类似热量限制的代谢作用。我们研究了达格列净对 2 型糖尿病患者 24 小时能量代谢和胰岛素敏感性的影响。
26 例 2 型糖尿病患者随机分为 5 周双盲交叉研究,洗脱期为 6-8 周。间接热量法通过整个房间热量计和通气罩在两步正糖高胰岛素钳夹期间测量 24 小时能量代谢和呼吸交换率(RER)。结果以治疗差异的最小二乘均数(95%CI)表示。
可评估的患者(n=24)平均(SD)年龄为 64.2(4.6)岁,BMI 为 28.1(2.4)kg/m,HbA 为 6.9%(0.7)(51.7[6.8]mmol/mol)。达格列净对葡萄糖清除率没有影响,而空腹内源性葡萄糖生成(EGP)增加了达格列净(+2.27[1.39,3.14]μmol/kg/min,<0.0001)。胰岛素诱导的 EGP 抑制(-1.71[-2.75,-0.63]μmol/kg/min,=0.0036)和血浆游离脂肪酸(-21.93%[-39.31,-4.54],=0.016)随达格列净增加。24 小时能量消耗(-0.11[-0.24,0.03]MJ/天)不受达格列净影响,但达格列净降低了日间和夜间的 RER,导致 RER 的日夜间差异增加(-0.010[-0.017,-0.002],=0.016)。达格列净治疗导致 24 小时能量和脂肪负平衡(-20.51[-27.90,-13.12]g/天)。
达格列净治疗 5 周可导致代谢发生重大调整,模拟热量限制,增加脂肪氧化,改善肝和脂肪胰岛素敏感性,并改善 24 小时能量代谢。